Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1748-717X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy ; volume:7 ; number:1 ; day:10 ; month:12 ; year:2012 ; pages:1-6 ; date:12.2012
Radiation oncology ; 7, Heft 1 (10.12.2012), 1-6, 12.2012

Urheber
Beteiligte Personen und Organisationen
Piroth, Marc D.
Holy, Richard
Djukic, Victoria
Klotz, Jens
Pfister, David
Heidenreich, Axel
Eble, Michael J.
SpringerLink (Online service)

DOI
10.1186/1748-717X-7-209
URN
urn:nbn:de:1111-2016072616731
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:59 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

Ähnliche Objekte (12)

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Biomarkers for prostate cancer: prostate-specific antigen and beyond

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy

Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy

Prostate-specific antigen-based screening: controversy and guidelines

Prostate-specific antigen-based screening: controversy and guidelines

Prostate-specific antigen testing accuracy in community practice

Prostate-specific antigen testing accuracy in community practice

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen

Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: a scoping review and meta-analysis

Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: a scoping review and meta-analysis

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer

Verbundene Objekte